{"slug":"guidelines","tag":"guidelines","variants":["guidelines"],"description":"People and collections that write or publish treatment guidelines.","count":18,"kinds":{"person":14,"collection":4},"related":[{"slug":"cll","tag":"cll","shared":2},{"slug":"esmo","tag":"esmo","shared":2},{"slug":"immunotherapy","tag":"immunotherapy","shared":2},{"slug":"thyroid","tag":"thyroid","shared":2},{"slug":"aml","tag":"aml","shared":1},{"slug":"breast","tag":"breast","shared":1},{"slug":"cervical","tag":"cervical","shared":1},{"slug":"classification","tag":"classification","shared":1},{"slug":"colorectal","tag":"colorectal","shared":1},{"slug":"de-escalation","tag":"de-escalation","shared":1},{"slug":"fixed-duration","tag":"fixed-duration","shared":1},{"slug":"gastric","tag":"gastric","shared":1}],"records":[{"id":"nadia-harbeck","kind":"person","name":"Nadia Harbeck","route":"/people/nadia-harbeck/","tldr":"German breast oncologist whose ADAPT trials use biology to decide who can have less chemotherapy."},{"id":"eric-van-cutsem","kind":"person","name":"Eric Van Cutsem","route":"/people/eric-van-cutsem/","tldr":"Led CRYSTAL, which established cetuximab in RAS wild-type colorectal cancer, and has shaped ESMO's GI guidelines for two decades."},{"id":"hedy-kindler","kind":"person","name":"Hedy L. Kindler","route":"/people/hedy-kindler/","tldr":"Senior investigator of POLO and a leader in mesothelioma trials, including the ASCO guidelines for the disease."},{"id":"florian-lordick","kind":"person","name":"Florian Lordick","route":"/people/florian-lordick/","tldr":"German GI oncologist who leads ESMO's gastric cancer guidelines and pivotal perioperative trials."},{"id":"silke-gillessen","kind":"person","name":"Silke Gillessen","route":"/people/silke-gillessen/","tldr":"Founder and chair of the APCCC consensus conference that guides advanced prostate cancer management worldwide."},{"id":"laurence-albiges","kind":"person","name":"Laurence Albiges","route":"/people/laurence-albiges/","tldr":"French kidney cancer specialist who co-led CheckMate 214 and the belzutifan trials."},{"id":"nicoletta-colombo","kind":"person","name":"Nicoletta Colombo","route":"/people/nicoletta-colombo/","tldr":"Led KEYNOTE-826, which made pembrolizumab plus chemotherapy the first-line standard for recurrent or metastatic cervical cancer."},{"id":"hartmut-dohner","kind":"person","name":"Hartmut Döhner","route":"/people/hartmut-dohner/","tldr":"Leads the European LeukemiaNet classification that defines how AML is diagnosed and risk-stratified worldwide."},{"id":"barbara-eichhorst","kind":"person","name":"Barbara Eichhorst","route":"/people/barbara-eichhorst/","tldr":"Led CLL13 (GAIA), showing venetoclax-based fixed-duration therapy beats chemoimmunotherapy in fit CLL patients."},{"id":"william-wierda","kind":"person","name":"William G. Wierda","route":"/people/william-wierda/","tldr":"Led CAPTIVATE, which established fixed-duration ibrutinib plus venetoclax as a first-line option for CLL."},{"id":"miguel-sanz","kind":"person","name":"Miguel A. Sanz","route":"/people/miguel-sanz/","tldr":"Spanish haematologist who led the PETHEMA trials that tailored acute promyelocytic leukaemia treatment to relapse risk, and who chaired the European LeukemiaNet recommendations for the disease."},{"id":"alexander-stratigos","kind":"person","name":"Alexander J. Stratigos","route":"/people/alexander-stratigos/","tldr":"Athens dermatologist who led the trial showing that cemiplimab works in advanced basal cell carcinoma after Hedgehog inhibitors have failed, and who co-authors the European skin cancer guidelines."},{"id":"bryan-haugen","kind":"person","name":"Bryan R. Haugen","route":"/people/bryan-haugen/","tldr":"Colorado endocrinologist who chaired the 2015 American Thyroid Association guidelines, the reference for how thyroid nodules and differentiated thyroid cancer are diagnosed and treated."},{"id":"keith-bible","kind":"person","name":"Keith C. Bible","route":"/people/keith-bible/","tldr":"Mayo Clinic oncologist who chaired the American Thyroid Association guidelines for anaplastic thyroid cancer, one of the fastest-growing human cancers."},{"id":"nice-guidance","kind":"collection","name":"NICE cancer guidance and technology appraisals (UK)","route":"/collections/nice-guidance/","tldr":"NICE decides which cancer treatments the NHS pays for, publishing for each drug an appraisal of cost per quality-adjusted life year against a threshold of about £20,000 to £30,000, plus clinical guidelines. Because the manufacturer models and committee reasoning are public, its decisions serve as an independent view of a drug's value that often diverges from FDA and EMA licensing."},{"id":"asco-guidelines","kind":"collection","name":"ASCO clinical practice guidelines","route":"/collections/asco-guidelines/","tldr":"ASCO guidelines are the American oncology society's guidelines, strongest on supportive care, survivorship, biomarker testing and resource-stratified recommendations for lower-income settings, complementing NCCN's algorithms."},{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","route":"/collections/csco-guidelines/","tldr":"CSCO guidelines are China's national oncology guidelines, covering about 30 cancers and updated annually. They grade each recommendation by both evidence level and affordability under China's reimbursement list, and they cover Chinese-developed drugs (PD-1 inhibitors, ADCs) and cancers common in China (nasopharyngeal, oesophageal, liver, gastric) years before Western guidelines."},{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","route":"/collections/jsmo-jsco-guidelines/","tldr":"The JSMO and JSCO guidelines are Japan's oncology guidelines, especially strong for gastric, oesophageal, liver and biliary cancers where Japanese trials set global standards (D2 gastrectomy, S-1, endoscopic resection), and for Japan's own approvals through PMDA."}]}